Jiyeon Jeon

Ms. Jiyeon Jeon

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2025
Verified
Preprint
Open access
SJSeongmee Jeong
Seongmee Jeong
WJWoo Jin Jung
Woo Jin Jung
JJJiyeon Jeon
Jiyeon Jeon
HJHyeong-Jun Jo
Hyeong-Jun Jo
KRKyoung-Bin Ryu
Kyoung-Bin Ryu
SLSoyoung Lee
Soyoung Lee
Aim: Sirolimus is currently used off-label for pediatric patients with vascular anomalies. However, the optimal dosage regimen for pediatric patients remains controversial. This study aimed to determine the optimal dosing regimen of sirolimus in these patients using a population pharmacokinetic (PK) model. Methods: Prospective study data (7 subjects) were used as the base model without covariates, while the retrospective study data (21 subjects) were used as the base model for external evaluation. The model was assessed using general model-building criteria, and a bootstrap stepwise covariate modeling method was used to identify relevant covariates. Simulations were performed for various scenarios to determine the optimal dosing regimen for maintaining sirolimus trough concentrations within a specific range. NONMEM software (version 7.5) with the first-order conditional estimation method with interaction was used. Results: The final sirolimus model was developed using a 2-compartment model, which was implemented by a maturation function using postmenstrual age (PMA), allometrically scaled body weight to account for size differences, and hemoglobin as a covariate on clearance. Simulations were conducted to propose an optimal dosing regimen. A once-daily dose of 0.01 – 0.1 mg/kg over one month maintained the trough concentration within the range of 5~15 ng/mL, taking into account patient-specific weight and the influence of hemoglobin constrained on PMA. The optimal dose varied by group, within the range of 0.05–0.09 mg/kg. Conclusions: We developed a robust and reliable PK model of sirolimus for pediatric patients with vascular anomalies. Pediatric optimal dosing regimens should be based on individual growth patients.

12 May 2026 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
SJSeongmee Jeong
Seongmee Jeong
JKJungryul Kim
Jungryul Kim
WJWoojin Jung
Woojin Jung
JJJiyeon Jeon
Jiyeon Jeon
HJHyeongjun Jo
Hyeongjun Jo
SLSoyoung Lee
Soyoung Lee
Aim: Sirolimus is currently used off‐label for paediatric patients with vascular anomalies. However, the optimal dosage regimen for paediatric patients remains controversial. This study aimed to determine the optimal dosing regimen of sirolimus in these patients using a population pharmacokinetic (PK) model. Methods: Prospective study data (seven subjects) were used as the structural model without covariates, while the retrospective study data (21 subjects) were used as the structural model with size and maturation functions for evaluation. The model was assessed using general model‐building criteria, and a bootstrap stepwise covariate modelling method was used to identify relevant covariates. Simulations were performed for various scenarios to determine the optimal dosing regimen for maintaining sirolimus trough concentrations within a specific range. NONMEM software (Version 7.5) with the first‐order conditional estimation method with interaction was used. Results: The final sirolimus model was developed using a two‐compartment model, which was implemented by a maturation function using postmenstrual age (PMA), allometrically scaled body weight to account for size differences, and haemoglobin as a covariate on clearance. Simulations were conducted to propose an optimal dosing regimen. A once‐daily dose of 0.01–0.1 mg/kg over 1 month maintained the trough concentration within the range of 5–15 ng/mL, taking into account patient‐specific weight and the influence of haemoglobin constrained on PMA. The optimal dose varied by group, within the range of 0.06–0.09 mg/kg. Conclusions: We developed a robust and reliable PK model of sirolimus for paediatric patients with vascular anomalies. Paediatric optimal dosing regimens should be based on individual growth patients.

24 March 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JJJihyun Jeon
Jihyun Jeon
JJJiyeon Jeon
Jiyeon Jeon
HDHuong Tra Dang
Huong Tra Dang
ECEun-Hyang Choi
Eun-Hyang Choi
SKSang Yull Kang
Sang Yull Kang
SLSoyoung Lee
Soyoung Lee
Background/Objectives: Although the Calvert formula has been widely used to guide carboplatin dosing, it may yield inaccurate dose predictions in certain patient populations. We aimed to evaluate the adequacy of the conventional Calvert formula and to propose structural modifications to enhance dosing accuracy in breast cancer patients with preserved renal function (CrCL ≥ 55 mL/min). Methods: A systematic review and meta-analysis were conducted to integrate published pharmacokinetic models in patients with breast cancer. Two retrospective datasets (n = 154) were combined into a single analysis dataset and used to calculate carboplatin doses based on the conventional formulas using creatinine clearance (CrCL) or estimated glomerular filtration rate (eGFR), as well as a modified formula incorporating an additional constant (α). Performance was assessed by the proportion of subjects achieving target area under the curve (AUC) attainment (4–6 mg·min/mL), underexposure (<4 mg·min/mL), and overexposure (≥7 mg·min/mL). All AUC metrics were derived from model-based predictions rather than measured carboplatin concentrations, and no clinical toxicities or efficacy outcomes were used for validation. Results: Meta-analysis yielded fixed-effect parameter estimates (CL: 131.8 mL/min, V1: 15.39 L, K12: 0.002 min−1, and K21: 0.003 min−1) with a random effect model. The conventional CrCL-based formula yielded 66.0% target attainment, 22.1% underexposure, and 4.5% overexposure. Switching to eGFR improved attainment to 88.3%, reduced underexposure to 5.8%, and lowered overexposure to 0.65%. A modified formula with α = 1 further decreased underexposure (4.5%) while target attainment and overexposure remained unchanged. Conclusions: Replacing CrCL with Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)-derived eGFR in the Calvert formula markedly improved dosing accuracy, while modest structural modification offered additional benefit. The incremental benefit of α = 1 should be considered hypothesis-generating and requires prospective validation with measured carboplatin concentrations and clinical outcomes before applying it in practice. These findings support adopting eGFR-based dosing in breast cancer and suggest the need for future clinical validation.